Sarepta Therapeutics (NASDAQ:SRPT) Given New $161.00 Price Target at Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT) had its target price cut by analysts at Royal Bank of Canada from $165.00 to $161.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price indicates a potential upside of 50.82% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Robert W. Baird reduced their target price on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Piper Sandler reduced their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, HC Wainwright reiterated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $173.52.

Sarepta Therapeutics Stock Up 3.6 %

SRPT stock opened at $106.75 on Thursday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 52-week low of $101.00 and a 52-week high of $173.25. The company has a 50-day moving average of $115.89 and a two-hundred day moving average of $122.61. The stock has a market capitalization of $10.20 billion, a price-to-earnings ratio of 85.40 and a beta of 0.75.

Insider Transactions at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently modified their holdings of SRPT. Blue Trust Inc. grew its stake in shares of Sarepta Therapeutics by 896.5% during the third quarter. Blue Trust Inc. now owns 568 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 511 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Sarepta Therapeutics by 59,222.7% during the third quarter. International Assets Investment Management LLC now owns 75,933 shares of the biotechnology company’s stock valued at $9,483,000 after purchasing an additional 75,805 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Sarepta Therapeutics by 112.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,002 shares of the biotechnology company’s stock valued at $747,000 after purchasing an additional 3,180 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of Sarepta Therapeutics by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 11,035 shares of the biotechnology company’s stock valued at $1,378,000 after purchasing an additional 750 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Sarepta Therapeutics by 16.9% during the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 155 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.